Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

Read More:
Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Scroll to Top